Aurinia Pharmaceuticals Inc.·4

Mar 3, 4:13 PM ET

Keenan Greg 4

4 · Aurinia Pharmaceuticals Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4
Period: 2026-02-27
Keenan Greg
SVP, Chief Medical Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-02-27+40,586162,518 total
  • Award

    Employee Stock Option (right to buy)

    [F2]
    2026-02-27+67,87067,870 total
    Exercise: $13.97Exp: 2036-02-27Common Stock (67,870 underlying)
Footnotes (2)
  • [F1]Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
  • [F2]One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Signature
/s/ Greg Keenan, M.D.|2026-03-03

Documents

1 file
  • 4
    wk-form4_1772572400.xmlPrimary

    FORM 4